Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
27 avr. 2021 10h02 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
04 mars 2021 07h05 HE
|
Sol-Gel Technologies Ltd.
• Epsolay® and Twyneo® PDUFA goal dates set for April 26, 2021 and August 1, 2021 respectively • Top-line generic product revenue of $8.7 million in fiscal 2020 • Signed additional generic product...
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
24 févr. 2021 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
11 janv. 2021 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
07 déc. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
- PDUFA Goal Date Set for August 1, 2021 - Potential to be the first acne treatment that contains a fixed-dose combination of benzoyl peroxide and tretinoin NESS ZIONA, Israel, Dec. 07, 2020 ...
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
12 nov. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
Epsolay® PDUFA goal date set for April 26, 2021Twyneo® New Drug Application submitted to the U.S. FDATop-line generic product revenue of $2.1 million in 3Q 2020In October 2020, signed an 11th generic...
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
09 nov. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
04 nov. 2020 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea
10 sept. 2020 16h01 HE
|
Sol-Gel Technologies Ltd.
- PDUFA Goal Date Set for April 26, 2021 - Potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product NESS ZIONA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Sol-Gel...
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September
08 sept. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...